Catalent (CTLT) Company Overview

Novo Holdings, the controlling shareholder of Novo Nordisk , hopes to double the size of its recently acquired contract drugmaker Catalent over five years, a senior partner at the investment firm said, as it prepares for a likely focus on U.S. manufacturing by President-elect Donald Trump.

Novo Holdings announced on Saturday that all regulatory requirements for its $16.5 billion purchase of U.S. drug manufacturer Catalent have been met. The companies expect to finalize the deal in the next few days.

Bagsværd, Denmark, 14 December 2024 — Today marks the completion of all regulatory requirements for Novo Holdings A/S's planned purchase of Catalent, Inc., including the end of the timing agreement in the US. Catalent, based in New Jersey, is a worldwide contract development and manufacturing organization. The companies can now proceed with the deal, along with Novo Nordisk's acquisition of three Catalent manufacturing facilities from Novo Holdings A/S.

SOMERSET, N.J. & COPENHAGEN, Denmark--(BUSINESS WIRE)--Catalent, Inc. (“Catalent,” NYSE: CTLT), a leader in improving treatments for patients globally, and Novo Holdings A/S (“Novo Holdings”), a worldwide life sciences investment firm, have announced that they have met all regulatory requirements for their upcoming deal. They anticipate finalizing the transaction in the next few days. “Today marks a significant milestone in our journey.”

Catalent, Inc. and Novo Holdings A/S have announced that the European Commission has given its unconditional approval for Novo Holdings to acquire Catalent. This approval is an important step in the process of the acquisition. Both companies are focused on improving treatments for patients around the world.

On Friday, Novo Holdings received full approval from the EU for its $16.5 billion purchase of the U.S. drug manufacturer Catalent, as EU regulators found no concerns regarding competition.

Catalent (CTLT) shared its earnings report 30 days ago. What can we expect for the stock moving forward?

EU antitrust regulators have requested opinions from pharmaceutical competitors and clients regarding four business sectors due to Novo Holdings' proposed $16.5 billion acquisition of Catalent, according to sources familiar with the situation.

Catalent (CTLT) reported a quarterly loss of $0.13 per share, which is worse than the Zacks Consensus Estimate of $0.11. This is also a decline from a loss of $0.10 per share the previous year.